MBK Partners to acquire Japanese drugmaker Alinamin
Private equity firm MBK Partners will acquire Japan’s Alinamin Pharmaceutical for 2.9 trillion won (US$2.1 billion), industry sources said Wednesday.
MBK Partners will buy the Japanese supplement maker from U.S. investment fund Blackstone in a stock…